Neurovirulence safety testing of mumps vaccines-Historical perspective and current status

Vaccine

Volumn 29, Issue 16, 2011, Pages 2850-2855

  Rubin, S A ^a   Afzal, M A ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Monkeys; Mumps; Neurovirulence; Safety; Vaccine

Indexed keywords

MUMPS VACCINE;

CALLITRICHINAE; DRUG SAFETY; HAPLORHINI; NEUROVIRULENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS VIRULENCE;

ANIMAL TESTING ALTERNATIVES; ANIMALS; CALLITHRIX; CRICETINAE; HAPLORHINI; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MENINGITIS, ASEPTIC; MICE; MUMPS VACCINE; MUMPS VIRUS; RATS; VACCINES, ATTENUATED; VIRULENCE;

EID: 79953194764     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.005     Document Type: Review

References (73)

1. Bruyn H.B., Sexton H.M., Brainerd H.D. Mumps meningoencephalitis. A clinical review of 119 cases with one death. Calif Med 1957, 86:153-160.
2. Strussberg S., Winter S., Friedman A., Benderly A., Kahana D., Freundlich E Notes on mumps meningoencephalitis. Some features of 199 cases in children. Clin Pediatr (Phila) 1969, 8(July (7)):373-374.
3. Bang H.O., Bang J. Involvement of the central nervous system in mumps. Acta Med Scand 1943, 113(6):487-505.
4. Hammer S.M., Connolly K.J. Viral aseptic meningtis in the United States: clinical features, viral etiologies, and differential diagnosis. Curr Clin Top Infect Dis 1992, 12:1-25.
5. Immunization Practices Advisory Committee Mumps prevention. MMWR 1989, 38(392):397-400.
6. Litman N., Baum SG Mumps virus. Principles and practice of infectious diseases 2010, 2201-2206. Churchill Livingstone, Philadelphia. 7 ed. G.L. Mandell, J.E. Bennett, R. Donlin (Eds.).
7. Aygun A.D., Kabakus N., Celik I., Turgut M., Yoldas T., Gok U., Guler R. Long-term neurological outcome of acute encephalitis. J Trop Pediatr 2001, 47(August (4)):243-247.
8. Xu Z.Q., Fu S.H., Zhang Y.P., Li X.L., Gao X.Y., Wang L., et al. [Laboratory testing of sepcimens from patients with viral encephalitis from some regions of China]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2008, 22(April (2)):98-100.
9. Karmarkar S.A., Aneja S., Khare S., Saini A., Seth A., Chauhan B.K. A study of acute febrile encephalopathy with special reference to viral etiology. Indian J Pediatr 2008, 75(August (8)):801-805.
10. Kanra G., Isik P., Kara A., Cengiz A.B., Secmeer G., Ceyhan M. Complementary findings in clinical and epidemiologic features of mumps and mumps meningoencephalitis in children without mumps vaccination. Pediatr Int 2004, 46(December (6)):663-668.
11. Anonymous. Mumps virus vaccine live. [CFR 21], 106-107. 4-1-1996. Office of the Federal Register, National Archives and Records Administration. Code of Federal Regulations; 1996.
12. World Health Organization. Requirements for measles, mumps and rubella vaccines and combined vaccine (live); 1994. Report No.: 840.
13. Balraj V., Miller E. Complications of mumps vaccines. Rev Med Virol 1995, 5:219-227.
14. Furesz J. Safety of live mumps virus vaccines. J Med Virol 2002, 67(July (3)):299-300.
15. Nagai T., Okafuji T., Miyazaki C., Ito Y., Kamada M., Kumagai T., et al. A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine 2007, 25(March (14)):2742-2747.
16. Sugiura A., Yamada A. Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 1991, 10(3):209-213.
17. Centers for Disease Control, Prevention Brief report: update: mumps activity-United States, January 1-October 7, 2006. MMWR Morb Mortal Wkly Rep 2006, 55(October (42)):1152-1153.
18. Centers for Disease Control Prevention Mumps epidemic-United Kingdom, 2004-2005. MMWR Morb Mortal Wkly Rep 2006, 55(Feb(7):):173-175.
19. Public Health Agency of Canada. Update on mumps outbreak in the Maritimes: national summary, October 26, 2007. http://www.phac-aspcgcca/mumps-oreillons/prof_e.html; 2007.
20. Schmid D., Pichler A.M., Wallenko H., Holzmann H., Allerberger F. Mumps outbreak affecting adolescents and young adults in Austria, 2006. Euro Surveill 2006, 11(June (6)):E060615.
21. Boxall N., Kubinyiova M., Prikazsky V., Benes C., Castkova J. An increase in the number of mumps cases in the Czech Republic, 2005-2006. Eurosurveillance 2008, 13(16).
22. Bernard H., Schwarz N.G., Melnic A., Bucov V., Caterinciuc N., Pebody R.G., et al. Mumps outbreak ongoing since October 2007 in the Republic of Moldova. Euro Surveill 2008, 13(March (13)):1-3.
23. Szomor K., Molnar Z., Huszti G., Ozsvarne C.E. Local mumps outbreak in Hungary, 2007. Euro Surveill 2007, 12(March (3)):E070329.
24. Kojouharova M., Kurchatova A., Marinova L., Georgieva T. Mumps outbreak in Bulgaria 2007 a preliminary report. Euro Surveill 2007, 12(March (3)):E070322.
25. Spanaki A., Hajiioannou J., Varkarakis G., Antonakis T., Kyrmizakis D.E. Mumps epidemic among young British citizens on the island of Crete. Infection 2007, 35(April (2)):104-106.
26. Castilla J., Garcia C.M., Barricarte A., Irisarri F., Nunez-Cordoba J.M., Barricarte A. Mumps outbreak in Navarre region, Spain, 2006-2007. Euro Surveill 2007, 12(2):E070215.
27. Levenbook I.S., Pelleu L.J., Elisberg B.L. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J Biol Stand 1987, 15(October (4)):305-313.
28. Furesz J., Contreras G. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines. Dev Biol Stand 1993, 78:61-70.
29. Levenbook I.S., Nikolayeva M.A., Chigirinsky A.E., Ralf N.M., Kozlov V.G., Vardanyan N.V., et al. On the morphological evaluation of neurovirulence safety of attenuated mumps virus strains in monkeys. J Biol Stand 1979, 7:9-19.
30. Maximova O., Dragunsky E.M., Taffs R.E., Snoy P., Cogan J., Marsden S., et al. Monkey neurovirulence test for live mumps vaccine. Biologicals 1996, 24:223-224.
31. Yuzepchuk S.A., Rozina E.E., Kaptsova T.I., Kulish E.A. Morphological differences in the central nervous system and organs of monkeys inoculated intracerebrally with virulent and attenuated strains of mumps virus. Acta Virol 1975, 19:305-310.
32. Rozina E.E., Hilgenfeldt M. Comparative study on the neurovirulence of different vaccine strains of parotitis virus in monkeys. Acta Virol 1985, 29(May (3)):225-230.
33. Miller E., Goldacre M., Pugh S., Colville A., Farrington P., Flower A., et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993, 341(April (8851)):979-982.
34. Black S., Shinefield H., Ray P., Lewis E., Chen R., Glasser J., et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997, 16(May (5)):500-503.
35. Ki M., Park T., Yi S.G., Oh J.K., Choi B. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. Am J Epidemiol 2003, 157(January (2)):158-165.
36. Colville A., Pugh M. Mumps meningitis and measles, mumps and rubella vaccine. Lancet 1992, 340:786.
37. Dourado I., Cunha S., Teixeira M.G., Farrington C.P., Melo A., Lucena R., et al. Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. Am J Epidemiol 2000, 151(March (5)):524-530.
38. Hockin J.C., Furesz J. Mumps meningitis, possibly vaccine-related-Ontario. Can Dis Wkly Rep 1988, 14(November (46)):209-211.
39. da Silveira C.M., Kmetzsch C.I., Mohrdieck R., Sperb A.F., Prevots D.R. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. Int J Epidemiol 2002, 31(October (5)):978-982.
40. Tesovic G., Lesnikar V. Aseptic meningitis after vaccination with L-Zagreb mumps strain-virologically confirmed cases. Vaccine 2006, 24(September (40-41)):6371-6373.
41. da Cunha S.S., Rodrigues L.C., Barreto M.L., Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. Vaccine 2002, 20(January (7-8)):1106-1112.
42. Arruda W.O., Kondageski C. Aseptic meningitis in a large MMR vaccine campaign (590,609 people) in Curitiba, Parana, Brazil, 1998. Rev Inst Med Trop Sao Paulo 2001, 43(September (5)):301-302.
43. Tischer A., Gerike E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000, 18(January (14)):1382-1392.
44. Ueda K., Miyazaki C., Hidaka Y., Okada K., Kusuhara K., Kadoya R. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet 1995, 346(September (8976)):701-702.
45. Odisseev H., Gacheva N. Vaccinoprophylaxis of mumps using mumps vaccine, strain Sofia 6, in Bulgaria. Vaccine 1994, 12:1251-1254.
46. Bonnet M.C., Dutta A., Weinberger C., Plotkin S.A. Mumps vaccine virus strains and aseptic meningitis. Vaccine 2006, 24(November (49-50)):7037-7045.
47. McCarthy M., Jubelt B., Fay D.B., Johnson R.T. Comparative studies of five strains of mumps virus in vitro and in neonatal hamsters: evaluation of growth, cytopathogenicity, and neurovirulence. J Med Virol 1980, 5:1-15.
48. Ennis F.A., Hopps H.E., Douglas R.D., Meyer H.M. Hydrocephalus in hamsters: induction by natural and attenuated mumps viruses. J Infect Dis 1969, 119:75-79.
49. Kilham L., Margolis G. Induction of congenital hydrocephalus in hamsters with attenuated and natural strains of mumps virus. J Infect Dis 1975, 132(4):462-466.
50. Wolinsky J.S., Stroop W.G. Virulence and persistence of three prototype strains of mumps virus in newborn hamsters. Arch Virol 1978, 57:355-359.
51. Tsurudome M., Yamada A., Hishiyama M., Ito Y. Replication of mumps virus in mouse: transient replication in lung and potential of systemic infection. Arch Virol 1987, 97(3-4):167-179.
52. Kristensson K., Orvell C., Malm G., Norrby E. Mumps virus infection of the developing mouse brain-appearance of structural virus proteins demonstrated with monoclonal antibodies. J Neuropathol Exp Neurol 1984, 43(March (2)):131-140.
53. Hayashi K., Ross M.E., Notkins A.L. Persistence of mumps viral antigens in mouse brain. Jpn J Exp Med 1976, 46(June (3)):197-200.
54. Overman J.R., Peers J.H., Kilham L. Pathology of mumps virus meningoencephalitis in mice and hamsters. Arch Pathol 1953, 55:457-465.
55. Popisil L., Brycthova J. Adaptation of the mumps virus to the albino rat (Wistar). Zentralbl Bakteriol Parasitenkd Infektionskr Hyg 1956, 165(1):1-8.
56. Rubin S.A., Pletnikov M., Carbone K.M. Comparison of the neurovirulence of a vaccine and a wild-type mumps virus strain in the developing rat brain. J Virol 1998, 72(10):8037-8042.
57. Rubin S.A., Pletnikov M., Taffs R., Snoy P.J., Kobasa D., Brown E.G., et al. Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans. J Virol 2000, 74(June (11)):5382-5384.
58. Buynak E.B., Hilleman M.R. Live attenuated mumps virus vaccine. 1. Vaccine development. Proc Soc Exp Biol Med 1966, 123(December (3)):768-775.
59. Rubin S.A., Afzal M.A., Powell C.L., Bentley M.L., Auda G.R., Taffs R.E., et al. The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study. J Infect Dis 2005, 191(April (7)):1123-1128.
60. Saika S., Kidokoro M., Aoki A., Ohkawa T. Neurovirulence of mumps virus: intraspinal inoculation test in marmosets. Biologicals 2004, 32(September (3)):147-152.
61. Saika S., Kidokoro M., Kubonoya H., Ito K., Ohkawa T., Aoki A., et al. Development and biological properties of a new live attenuated mumps vaccine. Comp Immunol Microbiol Infect Dis 2006, 29(March (2-3)):89-99.
62. Amexis G., Fineschi N., Chumakov K. Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain. Virology 2001, 287(August (1)):234-241.
63. Afzal M.A., Yates P.J., Minor P.D. Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain. J Infect Dis 1998, 177(January (1)):265-266.
64. Malik T.H., Sauder C., Wolbert C., Zhang C., Carbone K.M., Rubin S. A single nucleotide change in the mumps virus F gene affects virus fusogenicity in vitro and virulence in vivo. J Neurovirol 2007, 13(December (6)):513-521.
65. Love A., Rydbeck R., Ljungdahl A., Kristensson K., Norrby E. Selection of mutants of mumps virus with altered structure and pathogenicity by passage in vivo. Microb Pathog 1986, 1(April (2)):149-158.
66. Lemon K., Rima B.K., McQuaid S., Allen I.V., Duprex W.P. The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence. J Virol 2007, (May 2):8293-8302.
67. Boriskin Y., Kaptsova T.I., Lotte V.D., Skvortsova O.I., Orvell C. Laboratory markers for over-attenuation of mumps vaccine virus. Vaccine 1988, 6(December (6)):483-488.
68. Sauder C, Malik T, Rubin SA. Unpublished data.
69. Rozina E.E., Kaptsova T.I., Sharova O.K., Nikolayeva M.A., Nesterova T.P. Study of mumps virus invasiveness in monkeys. Acta Virol 1984, 28:107-113.
70. Sassani A., Mirchamsy H., Ahourai S.P., Razavi J., Gholami M.R., Mohammadi A., et al. Development of a new live attenuated mumps virus vaccine in human diploid cells. Biologicals 1991, 19:203-211.
71. Rubin S.A., Snoy P.J., Wright K.E., Brown E.G., Reeve P., Beeler J.A., et al. The mumps virus neurovirulence safety test in Rhesus monkeys: a comparison of mumps virus strains. J Infect Dis 1999, 180(August (2)):521-525.
72. Afzal M.A., Marsden S., Hull R.M., Pipkin P.A., Bently M.L., Minor P.D. Evaluation of the neurovirulence test for mumps vaccines. Biologicals 1999, 27:43-49.
73. Sasaki K., Higashihara N., Inoue K., Igarashi Y., Makino S. Studies on the development of a live attenuated mumps virus vaccine. I. Attenuation of the Hoshino " wild" strain of mumps virus. The Kitasato Archives of Experimental Medicine 1976, 49:43-52.